Protocol for a scoping review of outcomes in clinical studies of interventions for venous thromboembolism in adults. by Tritschler, Tobias et al.
1Tritschler T, et al. BMJ Open 2020;10:e040122. doi:10.1136/bmjopen-2020-040122
Open access 
Protocol for a scoping review of outcomes 
in clinical studies of interventions for 
venous thromboembolism in adults
Tobias Tritschler   ,1,2 Nicole Langlois,2 Brian Hutton   ,2 Beverley J Shea,2 
Risa Shorr,2 Sara Ng,2 Suzanne Dubois,3 Carol West,3 Alfonso Iorio,4 
Peter Tugwell,2 Grégoire Le Gal   2
To cite: Tritschler T, Langlois N, 
Hutton B, et al.  Protocol for a 
scoping review of outcomes in 
clinical studies of interventions 
for venous thromboembolism 
in adults. BMJ Open 
2020;10:e040122. doi:10.1136/
bmjopen-2020-040122
 ► Prepublication history and 
additional material for this paper 
is available online. To view these 
files, please visit the journal 
online (http:// dx. doi. org/ 10. 
1136/ bmjopen- 2020- 040122).
Received 06 May 2020
Revised 26 October 2020
Accepted 18 November 2020
1Department of General Internal 
Medicine, Inselspital, Bern 
University Hospital, University of 
Bern, Bern, Switzerland
2Department of Medicine, 
Ottawa Hospital Research 
Institute, University of Ottawa, 
Ottawa, Ontario, Canada
3Canadian Venous 
Thromboembolism Research 
Network (CanVECTOR), Patient 
Partner Platform, Ottawa, 
Ontario, Canada
4Department of Medicine, 
McMaster University, Hamilton, 
Ontario, Canada
Correspondence to
Dr Grégoire Le Gal;  
 glegal@ ohri. ca
Protocol
© Author(s) (or their 
employer(s)) 2020. Re- use 
permitted under CC BY- NC. No 
commercial re- use. See rights 
and permissions. Published by 
BMJ.
ABSTRACT
Introduction Venous thromboembolism (VTE) is a 
common, potentially fatal yet treatable disease. Several 
advances in treatment of VTE have been made over the 
past decades, but definition and reporting of outcomes 
across those studies are inconsistent. Development 
of an international core outcome set for clinical 
studies of interventions for VTE addresses this lack of 
standardisation. The first step in the development of a core 
outcome set is to conduct a scoping review which aims 
to generate an inclusive list of unique outcomes that have 
been reported in previous studies.
Methods and analysis MEDLINE, Embase and the 
Cochrane Central Register of Controlled Trials will be 
searched with no language restriction for prospective 
studies reporting on interventions for treatment of VTE in 
patients who are adult and non- pregnant. Records will be 
sorted in reverse chronological order. Study screening and 
data extraction will be independently performed by two 
authors in blocks based on date of publication, starting 
with 2015 to 2020 and subsequent 1- year periods, until 
no new outcome measures are identified from the set 
of included studies. After homogenising spelling and 
combining outcomes with the same meaning, a list of 
unique outcomes will be determined. Those outcomes will 
be grouped into outcome domains. Qualitative analysis and 
descriptive statistics will be used to report results.
Ethics and dissemination Ethical approval is not 
required for this study. The results of this scoping review 
will be presented at scientific conferences, published in 
a peer- reviewed journal, and they will provide candidate 
outcome domains to be considered in subsequent steps in 
the development of a core outcome set for clinical studies 
of interventions for VTE.
Protocol registration details http:// hdl. handle. net/ 
10393/ 40459
INTRODUCTION
Rationale
Venous thromboembolism (VTE) is a 
common condition manifested as deep 
vein thrombosis (DVT) or pulmonary 
embolism (PE). If left untreated, the 
reported mortality of PE has varied widely 
in historical and more recent studies,1 2 
but timely and appropriate treatment with 
anticoagulant medications dramatically 
reduces fatal events to less than 1%.3 In addi-
tion to PE- related death, most VTE treat-
ment studies incorporate recurrent VTE or 
bleeding as primary or secondary outcomes. 
However, it has been noted that the list, 
definition and reporting of outcomes is 
inconsistent across studies and discrepan-
cies in how these outcomes are defined and 
measured have led to important challenges 
in comparing and synthesising the results 
of trials.4 Lack of valid and standardised 
definitions of domains and measures for 
certain outcomes has also compromised the 
ability to demonstrate clinically meaningful 
effects. For example, how severe a bleeding 
event should be to count as an outcome has 
been a matter of debate.5 The definition of 
PE- related death is variable between studies,6 
and within a single study the outcome adju-
dicators demonstrated poor reproducibility 
(50% discordant results) for unexplained 
sudden death adjudicated as PE- related.7 
Beneficial and safety outcomes beyond 
mortality, recurrent VTE and bleeding, such 
as post- thrombotic syndrome, quality of life, 
symptom resolution or psychological effects, 
are rarely measured in VTE studies,8 9 even 
though their impact on patients’ health and 
Strengths and limitations of this study
 ► The study will aim to provide a comprehensive review 
of all outcomes that have been reported in clinical 
studies of treatment for venous thromboembolism.
 ► The study will use best practice methods to conduct 
a scoping review.
 ► Randomised controlled trials and prospective cohort 
studies will be eligible.
 ► We will determine a list of unique outcomes and 
group those outcomes into domains.
 ► We will involve patient partners throughout the study 
planning, conduct and dissemination.
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economic burden of VTE may be relevant. Of note, no 
study to date has assessed which outcomes are most 
important to patients and caregivers.
The development of a core outcome set (COS), defined 
as an agreed minimum set of outcomes that should be 
measured and reported in all trials of a specific condi-
tion, addresses this lack of standardisation. The Core 
Outcome Measures in Effectiveness Trials (COMET) 
and Outcome Measures in Rheumatology (OMERACT) 
initiatives aim to stimulate the development and appli-
cation of COS, adopting best practices and robust meth-
odology that are based on evidence.10 11 The first step in 
the development of a COS includes a scoping review of 
the literature to identify outcomes and domains that have 
been used previously. The results of the scoping review 
will help to determine the heterogeneity of reported 
outcomes and establish a list of unique outcomes. The 
results of this scoping review, considered together with 
the findings of other planned qualitative work involving 
multiple stakeholders (including patients, caregivers, 
clinicians, researchers, clinical practice guideline devel-
opers, health technology assessors, payers, policymakers, 
public research funding agencies and drug developers), 
will inform candidate outcomes and domains for the 
final consensus process to determine the COS for clinical 
studies of interventions for VTE.
Objectives
Primary objective
The primary objective of the scoping review is to generate 
an inclusive list of unique outcome domains that have 
been reported in previous VTE treatment studies.
Secondary objectives
The secondary objectives are to assess the number 
of unique outcome domains and measures reported 
(ie, outcome reporting heterogeneity),12 to assess the 
number of unique outcomes reported per study, to assess 
the presence of different wording for the same outcomes, 
to assess different time points at which unique outcomes 
are measured, to assess the number of patient- reported 
unique outcomes and to capture outcome definitions.
METHODS AND ANALYSIS
This protocol was developed following guidance in the 
COMET and OMERACT handbooks and reporting 
adheres to the Preferred Reporting Items for Systematic 
Review and Meta- Analysis Protocols (PRISMA- P) state-
ment.10 11 13 The protocol of this scoping review has been 
registered with the University of Ottawa’s digital repos-
itory of research (available at http:// hdl. handle. net/ 
10393/ 40459) and the VTE- COS project is registered 
with the COMET database (http://www. comet- initiative. 
org). Reporting of the scoping review will adhere to the 
PRISMA statement items on scoping reviews.14
Eligibility criteria
Participants
We will seek studies that enrolled adults diagnosed with 
VTE, either DVT of the legs, PE or both. We will exclude 
VTE studies which included only pregnant women, 
comprising the antepartum, peripartum and postpartum 
periods, because an ongoing systematic review already 
assesses reported outcomes in this specific population 
(PROSPERO registration number CRD42019111479).
Interventions
We are interested in nine categories of interventions 
for treatment of VTE: (1) anticoagulation; (2) aspirin 
and other non- steroidal anti- inflammatory drugs; (3) 
statins; (4) thrombolysis; (5) surgery; (6) venous filters; 
(7) pharmacomechanical catheter- directed thrombolysis; 
(8) venous angioplasty and stenting; and (9) compres-
sion stockings. Studies involving the evaluation of other 
therapies will be excluded. Because of the wide range 
of treatment options for VTE, some outcome domains 
may only be relevant to certain therapies or subpop-
ulation of patients. While these may not be mandatory 
domains in the final core outcome set, they may repre-
sent important but optional domains or research agenda 
domains according to the OMERACT onion schema.11 As 
such, the categorisation of interventions will not only be 
collected to characterise included studies but also consid-
ered in study selection and data extraction (see ‘data 
management and selection process’).
Outcome
This review will capture all outcomes reported in the 
included studies. Each component of a composite 
outcome will be considered as single outcome.
Study design
Randomised controlled trials and prospective cohort 
studies will be eligible.
Search strategy
An experienced information specialist developed the 
strategy for structured database searches in consul-
tation with the review team. The search strategy was 
peer reviewed according to the Peer Review of Elec-
tronic Search Strategies (PRESS) guideline statement 
by a second independent information specialist before 
being finalised.15 Databases to be searched will include 
MEDLINE, Embase and the Cochrane Central Register 
of Controlled Trials. No language restrictions will be in 
place. The search strategy for MEDLINE, Embase and the 
Cochrane Central Register of Controlled Trials for the 
first blocks of studies to be screened (ie, 2014 and 2015 
to 2020; see ‘data management and selection process’) is 
provided in the online supplemental appendix.
Data management and selection process
Screening of studies at both the title/abstract level (Level 
1 screening) and the full- text level (Level 2 screening) 
will be implemented in Covidence, an online software 
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management programme for the performance of system-
atic reviews.16 All documents will be reviewed inde-
pendently by two team members. Disagreement will be 
resolved by discussion or by involving a third reviewer, if 
needed. A flow diagram summarising the process of study 
selection will be prepared.
To maximise efficiency of the study selection process, 
titles/abstracts for Level 1 screening will be sorted in 
reverse chronological order and will be screened in blocks 
based on date of publication. To begin, studies published 
between 2015 and 2020 will be screened at both abstract 
and full- text level to establish a full set of included studies 
for this time period. Data extraction from these studies 
(methods described below) will be performed in full to 
establish a complete ‘map’ of all the outcomes measured 
in the set of included studies. Subsequently, in 1- year 
intervals (ie, 2014, 2013, 2012 and so on), the same 
approach will be taken; selection of additional studies for 
inclusion will be halted when, for a 1- year period, no new 
outcome measures are identified from the set of included 
studies (commonly referred to as ‘saturation’ in terms of 
outcome measures). This approach is recommended by 
COMET and OMERACT guidance and results in a robust 
source of information for the review while offering effi-
ciencies in both study selection and data extraction.10 11 
Because studies assessing different categories of inter-
ventions may be variably represented over time, satura-
tion will be assessed for each of the nine above- defined 
intervention categories. If a certain category is not repre-
sented by at least one study within one of the assessment 
periods (ie, 2015 to 2020 and subsequent 1- year periods), 
selection of additional studies will not be halted for this 
particular category.
Data extraction
For all included studies identified using the above 
approach, extracted data from each report will include 
the characteristics of the study (design, year, country, 
interventions, follow- up duration), as well as the set 
of reported outcomes, outcome definitions, outcome 
measurement tools, timing of measurement and metrics. 
Outcome descriptions will be extracted verbatim. All data 
of interest will be extracted from the source publications 
by two authors independently. Corresponding authors 
of selected studies will be contacted for clarification on 
details of the reported outcomes, if needed.
Outcomes and prioritisation
The primary outcome of the study is a list of unique 
outcomes reported in the included studies. A unique 
outcome will be defined as one that has original meaning 
and context.12 Outcomes differing only in timing of 
the outcome assessment (eg, 10- day vs 30- day all- cause 
mortality) will not be considered unique. We will extract 
outcomes verbatim and also record each outcome’s defi-
nition, timing of assessment, measurement and metrics. 
The selection process of unique outcomes will follow 
the proposal of Young et al.12 First, duplicate verbatim 
outcomes will be removed after homogenising spelling 
(eg, bleeding and bleed, rates and rate and so on). 
Second, outcomes meaning the same will be rewritten 
by two reviewers independently to develop non- verbatim 
outcomes. The rewriting process will be documented. 
Finally, outcomes remaining after removal of duplicate 
non- verbatim outcomes will define the list of unique 
outcomes.
Risk of bias (quality) assessment
Given that the purpose of this review is to develop an 
inclusive set of outcome domains in order to inform 
subsequent steps in the VTE- COS development, no risk of 
bias assessment will be performed. This is consistent with 
recommendations in the PRISMA extension for scoping 
reviews.14
Data synthesis
We will use descriptive statistics to report the number of 
verbatim outcomes reported overall and in each indi-
vidual study and the number of terms used to describe 
a single unique outcome. Furthermore, we will report 
the number of unique outcomes overall and per study, 
definitions of unique outcomes including time points of 
assessment, as well as the number of physician- reported 
and patient- reported unique outcomes.
Similar unique outcomes will be grouped into domains. 
A domain is defined as a component or concept of ‘an 
aspect of health or health condition that needs to be 
measured to appropriately assess the effects of a health 
intervention’.11 Once several domains have been iden-
tified, outcomes within domains will be checked for 
internal homogeneity (ie, coherence of outcomes within 
domain) and external heterogeneity (ie, distinction to 
outcomes in other domains).17 As per OMERACT filter 
2.1, the final list of domains will be categorised into four 
core areas including manifestations/abnormalities, life 
impact, death/lifespan and societal/resource use.18
We will use descriptive statistics to report the number 
of domains and core areas covered in each individual 
study and vice versa. In subgroup analyses, we will assess 
differences related to above- mentioned descriptive statis-
tics between randomised controlled trials and prospective 
cohort studies, and between different locations of initial 
VTE (ie, studies for which patients were eligible if they 
had DVT vs PE vs VTE).
Confidence in cumulative evidence
Because we aim to capture and describe what outcomes 
have been reported in previous VTE studies, determina-
tion of the strength of evidence is not applicable.
Patient and public involvement
Patient partners of the Canadian Venous Thrombo-
embolism Clinical Trials and Outcomes Research 
(CanVECTOR) Network are members of the Steering 
Committee of the VTE- COS project. As persons with 
lived experience or relatives thereof, they provided 
insights about patient- relevant aspects of the project and 
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contributed to the concept and protocol of this scoping 
review. They will review the outcome domains and the 
final manuscript, and will be involved in the dissemina-
tion of the results by providing assistance in writing lay 
evidence summaries which will also serve as basis for 
discussion in subsequent steps of the COS development.
ETHICS AND DISSEMINATION
Ethical approval is not required for this study because this 
is a scoping review of published studies.
In this scoping review, we aim to generate a list of 
unique outcome domains reported in previous studies of 
VTE treatment. This list will serve to define core domains 
to be considered in the development of a COS for VTE 
treatment studies. Subsequent steps of the COS develop-
ment project include (1) individual interviews and focus 
groups of different stakeholders to identify additional 
candidate domains which are important for patients 
and other stakeholders and to increase understanding 
of stakeholder- relevant outcomes; (2) a Delphi survey to 
add additional previously not identified outcomes and to 
prioritise outcomes; (3) a consensus meeting among the 
study researchers and key stakeholders to define the final 
COS; and (4) the dissemination of the final COS.
The findings of this scoping review will be disseminated 
through a peer- reviewed journal publication and presen-
tations at scientific conferences. As part of the VTE- 
COS project, the study is endorsed by the International 
Society on Thrombosis and Haemostasis (ISTH), the 
CanVECTOR network and the International Network of 
VENous Thromboembolism Clinical Research Networks 
(INVENT). In addition to publication and presenta-
tion of the study findings, we will use their platforms to 
foster dissemination of results to researchers, knowledge 
users and patients in form of audience- specific summary 
reports.
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